— Know what they know.
Not Investment Advice
Also trades as: HUMAW (NASDAQ) · $vol 0M

HUMA NASDAQ

Humacyte, Inc.
1W: +2.0% 1M: +44.7% 3M: -9.7% YTD: +4.6% 1Y: -59.0% 3Y: -73.8% 5Y: -89.7%
$1.05
+0.03 (+2.94%)
 
Weekly Expected Move ±19.4%
$1 $1 $1 $1 $1
NASDAQ · Healthcare · Biotechnology · Alpha Radar Buy · Power 62 · $176.4M mcap · 138M float · 5.04% daily turnover · Short 65% of daily vol

Cash Flow Trends

Operating Cash Flow
-$105M -7.1% ▼
Capital Expenditures
$884K +43.8% ▲
5Y CAGR: +22.7%
Free Cash Flow
-$106M -6.3% ▼
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
-$44M -406.7% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
— Operating Activities —
Net Income-$26M-$12M-$111M-$149M-$41M
Depreciation & Amort.$8M$8M$8M$7M$5M
Stock-Based Comp.$10M$6M$0$6M$10M
Change in Working Capital-$557K$1M$7M$311K-$23M
Other Non-Cash Items-$73M-$75M$23M$37M-$56M
Operating Cash Flow-$81M-$71M-$73M-$98M-$105M
— Investing Activities —
Capital Expenditures-$220K-$1M-$2M-$2M-$884K
Acquisitions (Net)$0$0$0$0$0
Investment Purchases-$8M-$10M$0$0$0
Investment Sales$0$16M$2M$0$0
Other Investing$0$0$0$0$0
Investing Cash Flow-$8M$5M-$173K-$2M-$884K
— Financing Activities —
Net Debt Issuance$28M-$2M$6M-$3M$36M
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$239M$535K-$2M$28M-$88M
Financing Cash Flow$267M-$1M$5M$114M$61M
Net Change in Cash$178M-$68M-$69M$14M-$44M
Cash End of Period$218M$150M$81M$95M$51M
Free Cash Flow-$81M-$72M-$76M-$100M-$106M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms